Pembrolizumab Wins FDA Approval in Operable Lung Cancer
(MedPage Today) -- The FDA approved pembrolizumab (Keytruda) on Monday in combination with platinum-based chemotherapy for the perioperative treatment of resectable non-small cell lung cancer (NSCLC).
Approval was based on improved event-free... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 17, 2023 Category: Hematology Source Type: news
Cancer on the baby monitor: Parents who spotted strange mark on their son's eye are told they were result of rare TUMOR
Benny was only six months old when doctors diagnosed him with retinoblastoma - a type of cancer in the eye. The boy from Utah was treated using chemotherapy. (Source: the Mail online | Health)
Source: the Mail online | Health - October 17, 2023 Category: Consumer Health News Source Type: news
FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell lung cancer
On October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as post-surgical adjuvant treatment for resectable (tumors ≥4 cm or node positive) non-sm (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 16, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Venus Remedies gets marketing approval for six chemotherapy drugs from Philippines
Venus Remedies has already submitted dossiers to the Health Ministry of the Philippines for additional 45 marketing authorisations, and most of these pending approvals are for oncology products, it said. Pertinently, the market size of cancer drugs in the Philippines was valued at USD 252 million in 2020 and is expected to grow at a compound annual growth rate of 8.7 per cent by 2025. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 16, 2023 Category: Pharmaceuticals Source Type: news
FDA Approves Keytruda (pembrolizumab) for Treatment of Patients With Resectable NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Single Agent as Adjuvant Treatment After Surgery
RAHWAY, N.J.--(BUSINESS WIRE) October 16, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda , Merck’s anti-PD-1 therapy, for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 16, 2023 Category: Drugs & Pharmacology Source Type: news
Patients with rare cancers given hope by UK-led ‘drug-match’ trial
Tumours reduce with treatment licensed for more common cancersLisa Park was 48 when she was admitted to A&E in 2019 with worsening bouts of abdominal pain. Her eventual diagnosis was unexpected. She was told she was suffering from gallbladder cancer, a rare but serious condition that usually only affects people in old age.Surgery and chemotherapy eradicated the tumours, but after a few months the cancer returned. “I was given a year to live,” said Park. It was a grim diagnosis, yet her prospects have recently taken an unexpected turn for the better.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - October 14, 2023 Category: Science Authors: Robin McKie Science Editor Tags: Cancer research Medical research Science Health Society University of Manchester UK news Source Type: news
6 Stories Show the Human Toll of Poland ’ s Strict Abortion Laws
This project was supported by the Pulitzer Center
[time-brightcove not-tgx=”true”]
Krzysztof Sowinski has cried every day since his wife Marta, who was five months pregnant, died of sepsis in 2022; he believes doctors put Marta’s life in danger by not giving them the option to terminate the pregnancy while the fetus’ heart was still beating. Janusz Kucharski also lost his partner Justyna to sepsis in the fifth month of a pregnancy. She left behind two boys.
It is likely, reproductive-rights advocates say, that these women would be alive if not for Poland’s increasingly restrictive abort...
Source: TIME: Health - October 13, 2023 Category: Consumer Health News Authors: Anna Pamula Tags: Uncategorized abortion Source Type: news
Session 4: mCRPC: Which Treatment Option Would You Pursue? Session 4: mCRPC: Which Treatment Option Would You Pursue?
Session 4 focuses on mCRPC management including discussions on chemotherapy, radionuclides, and PARP inhibitors.Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 13, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
ESMO 2023: A Wealth of New Data Across Cancer Types ESMO 2023: A Wealth of New Data Across Cancer Types
The march of immunotherapy into a wider range of malignancies, as well as the smarter use of chemotherapy and novel targeted drugs, will be among the key highlights at the ESMO Congress 2023.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 11, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Tumor Destroyer? FDA approves tool that uses ultrasound to fight cancer
The U.S. Food and Drug Administration has approved a new non-invasive technique developed at the University of Michigan to treat certain cancers, avoiding chemotherapy, radiation and even surgery. The technique is called histotripsy, stemming from the Greek terms of histo and tripsy. Histo means…#universityofmichigan #greek #edison #mishalmendriattalala #histotripsy #mendriattalala #histosonics #rogelcancercenter #fda #zhenxu (Source: Reuters: Health)
Source: Reuters: Health - October 9, 2023 Category: Consumer Health News Source Type: news
NCCN: Cancer Centers Still Experiencing Shortages of Chemo Drugs
THURSDAY, Oct. 5, 2023 -- Many cancer centers are still experiencing a shortage of carboplatin, cisplatin, and other chemotherapy drugs, according to the results of a follow-up survey conducted Sept. 6 to 20, 2023, by the National Comprehensive... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 5, 2023 Category: Pharmaceuticals Source Type: news
Cancer Drug Shortages Persist Across U.S.
THURSDAY, Oct. 5, 2023 -- U.S. cancer centers continue to have shortages of commonly used chemotherapy drugs, a new survey shows, though the medications are not as scarce as they were last June.
The National Comprehensive Cancer Network (NCCN), a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 5, 2023 Category: General Medicine Source Type: news
Surgery and other medical procedures are delayed by the Kaiser strike, patients say
Operations were rescheduled, chemotherapy treatments were canceled and other procedures deemed “non-urgent” were postponed as tens of thousands of health care workers nationwide began to strike Wednesday. In what union leaders call the largest health care worker strike in U.S. history, more than…#kaiserpermanente #colorado #oregon #virginia #sacramento #cadenyoung #tiffanyyoung #modesto #johnschnaidt #kaiser (Source: Reuters: Health)
Source: Reuters: Health - October 4, 2023 Category: Consumer Health News Source Type: news
Add Chemo for Fit Patients With EGFR-Mutant Lung Cancer Add Chemo for Fit Patients With EGFR-Mutant Lung Cancer
Mark Kris, MD, discusses the addition of chemotherapy for newly diagnosed EGFR-mutant lung cancers.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 2, 2023 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Breakthrough in the fight against resistance in metastatic breast cancer
A team of researchers at the Medical University of Vienna has discovered that dormant tumor cells surviving chemotherapy can be targeted through the inhibition of a specific protein called P-glycoprotein (P-gp). This discovery opens up new possibilities for delaying relapse and is particularly relevant for aggressive triple-negative breast cancer (TNBC), for which there are currently few effective treatments. (Source: World Pharma News)
Source: World Pharma News - October 2, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
